Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
Holding CMPS?
Track your performance easily
CMPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.17 - $12.75
Previous CloseN/A
Volume477.34K
Average Volume (3M)1.01M
Market Cap
$233.31M
Enterprise Value$256.10M
Total Cash (Recent Filing)$22.91M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Feb 26, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding92,435,550
10 Day Avg. Volume1,550,684
30 Day Avg. Volume1,012,270
Standard Deviation0.21
R-Squared0.26
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$22.38Price Target Upside541.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
COMPASS Pathways News
PremiumCompany Announcements
COMPASS Pathways Boosts Funds for Mental Health Trials
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCOMP360 appears on track for a positive outcome from its Phase 3 program in treatment-resistant depression.
Company StrategyCOMPASS is seen as a pioneer in the psychedelics drug development field, with management making strategic moves to enhance the success probability in treating depression.
Investment OpportunityThe pullback on the shares is seen as a particularly good opportunity to BUY the stock.
Bears Say
Market Entry DelayMarket entry for COMP360 has been pushed back by one year to 2028, leading to increased uncertainty about future earnings potential.
Trial DelaysThe anticipated data readouts for the Phase III COMP360 program in treatment-resistant depression have been delayed for both the COMP005 and COMP006 trials, causing disappointment among investors.
Workforce ReductionManagement plans to reduce the workforce by approximately 30% to focus resources on the execution of the Phase III program, which reflects the challenges arising from the delay.
---
Ownership Overview
22.10% Insiders
0.22% Mutual Funds
0.23% Other Institutional Investors
74.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $3.17 and its highest was $12.75 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $233.31M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Feb 26, 2025 which is in 38 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Oct 31, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.01.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.63.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 92,435,550 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went down -23.102%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 13M.
---
COMPASS Pathways Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.38 (541.26% Upside)
$22.38 (541.26% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.43%
12-Months-Change
Fundamentals
Return on Equity
-64.99%
Trailing 12-Months
Asset Growth
-17.29%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
CMPS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial management and commercial preparation, but significant trial delays and organizational downsizing indicate challenges. While there are positive aspects to the company's progress, the delays and workforce reductions weigh heavily on the overall sentiment.Read More>---
CMPS Stock 12 Month Forecast
Average Price Target
$22.38
▲(541.26% Upside)
Technical Analysis
Mind Medicine
―
ATAI Life Sciences
―
Relmada Therapeutics
―
Cybin
―
GH Research
―
Anavex Life Sciences
―
Best Analysts Covering CMPS
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-36.87%
reiterated a buy rating 10 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -36.87% per trade.
---